Skip to content
Markets

Roche Shares Climb as Divarasib Cuts the Risk of Death by 44% in Lung Cancer

Roche shares opened about 1.5% higher on Monday after divarasib cut the risk of death by 44% against approved KRAS G12C drugs in a Phase III lung cancer trial, extending an 11.7% three-week rally.

Roche Building 1 and Building 2 towers at the Basel headquarters, 2023 (5616 x 3744 jpeg)
Photo: Roche

Roche shares opened about 1.5% higher in Zurich on Monday after the Swiss drugmaker said its experimental lung cancer pill divarasib cut the risk of death by 44% against the two KRAS G12C drugs already on the market. The data extend a run that lifted the stock 11.7% in three weeks, to CHF 397.40 at Friday's close.

A head-to-head win against approved drugs

The Phase III Krascendo 1 trial compared divarasib with sotorasib or adagrasib, the two approved drugs that block the same KRAS G12C mutation, in 338 adults with advanced non-small cell lung cancer who had already been treated. Beating the existing standard is a harder test than beating chemotherapy or placebo, and a clear win suggests divarasib could take share in an established class rather than wait for a new one.

Patients on divarasib lived for a median of 17.7 months, against 12.0 months in the control arm, a hazard ratio of 0.56. The trial's main goal, progression-free survival judged by independent reviewers, also went divarasib's way: 9.8 months against 5.7 months, a 42% lower risk of the cancer growing or the patient dying. The confirmed response rate was 58%, close to double the 32% in the control arm.

Krascendo 1 trial

  • -44% risk of death vs. sotorasib or adagrasib
  • 17.7 months median survival, vs. 12.0 months
  • 58% response rate, vs. 32%

Tolerability also favoured the Roche drug. Only 4.8% of patients on divarasib stopped treatment because of side effects linked to the drug, against 11.7% in the control arm, and serious treatment-related side effects ran at 7.8% against 15.2%. The most common problems were gastrointestinal and liver-related and mostly mild, and Roche said it saw no new safety signals.

The results were presented on Sunday as a late-breaking abstract in a Presidential Symposium at the ESMO congress in Madrid and published at the same time in the New England Journal of Medicine. The study's lead author, Ferdinandos Skoulidis, called divarasib "the first KRAS inhibitor to meaningfully improve overall survival".

A scientist in safety goggles and lab coat at equipment in a Roche laboratory while a colleague watches (6000 x 4000 jpeg).
A scientist in safety goggles and lab coat at equipment in a Roche laboratory while a colleague watches (6000 x 4000 jpeg). Photo: Roche

Roche: share price, chart and news

What comes next for divarasib

Roche said it is working with health authorities to make the drug available but gave no timetable for filings. The US Food and Drug Administration granted divarasib Breakthrough Therapy Designation in 2022 and Orphan Drug Designation for this type of lung cancer in 2026.

The bigger commercial prize lies earlier in the disease. Krascendo 2 is testing divarasib with the immunotherapy pembrolizumab, without chemotherapy, as a first treatment against chemotherapy plus pembrolizumab. Krascendo 3 is testing it after surgery in stage II to IIIB disease. Neither has reported yet, and both would reach far more patients than the previously treated group in Krascendo 1.

Results set the tone last week

The trial news arrived four days after Roche's nine-month update. Group sales reached CHF 46.5bn, up 6% at constant exchange rates but only 1% in Swiss francs because of the strong franc. That currency drag reversed in the third quarter, when sales rose 7% at constant rates and 8% in francs.

Pharmaceuticals sales were CHF 36.2bn, up 7% at constant rates, and Diagnostics CHF 10.3bn, up 4%. Five medicines did most of the work: Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo together sold CHF 16.8bn, up 12%. Roche confirmed, rather than raised, its 2026 outlook for mid-single-digit sales growth and high-single-digit growth in core earnings per share at constant rates, and it still expects to raise its dividend in francs.

Investors did not need an upgrade. The shares rose 3.33% in the week to 23 October, after gains of 4.91% and 3.04% in the two weeks before, and Deutsche Bank upgraded the stock to Buy on 23 October.

What investors watch now

The first question is how much of the divarasib result was already in the price after three weeks of gains. The ESMO congress runs until Tuesday, so more cancer data will reach the market this week.

Beyond that, the market will look for a filing date for divarasib, for the first readouts from Krascendo 2 and 3, and for decisions on medicines already under review, including the US Priority Review for fenebrutinib in multiple sclerosis that Roche listed with its results. The Swiss franc remains the main swing factor for the reported numbers.

Sources

Related stories

Markets

Roche's Sales Growth Speeds Up to 7% in the Third Quarter as It Confirms Its 2026 Outlook

Roche's third-quarter sales rose 7% at constant currencies and 8% in Swiss francs, taking nine-month sales to CHF 46.5bn. The group confirmed its 2026 targets as Xolair, Hemlibra…

Business

Roche Wins FDA Approval for Breast Cancer Pill Wilserdly After 62% Cut in Progression Risk

The FDA approved Roche's all-pill Wilserdly combination for ESR1-mutated advanced breast cancer after it cut the risk of progression or death by 62%. A ruling on early-stage use is…

Markets

Novartis Raises Its Profit Outlook Despite a $1.9bn Writedown on Del-desiran

Novartis raised its 2026 profit guidance as Q3 core operating income rose 10% to $6.04bn, beating the $5.51bn expected, even as a $1.9bn del-desiran writedown cut reported profit…

Markets

GSK Shares Fall Nearly 5% as Shingrix and Arexvy Miss Forecasts Despite a Profit Beat

GSK shares fell 4.7% to 1,834p after Shingrix and Arexvy vaccine sales missed forecasts by 8% and 16%, overshadowing third-quarter core operating profit of £3.08bn that beat the…

Markets

Bitcoin Falls to $62,000 as $2bn of Leveraged Bets Are Wiped Out in Sixth Weekly Loss

Bitcoin fell to about $62,000 at the weekend as $2bn of leveraged bets were liquidated, its sixth straight weekly loss. It was back near $65,000 on Monday, with $60,000 the next…

Markets

Copper Hits a Four-Month Low at $13,210 as AI Doubts Drag European Miners Down 2.3%

Copper fell to $13,210 a tonne on Monday, a four-month low about 10% below September's record, as AI doubts and weak Chinese data hit metals and Europe's basic resources shares…

Markets

Bessent Urges an Outside CEO for Nvidia as Shares Fall 4.1% Before Results

Treasury Secretary Scott Bessent wants Nvidia to hire an outside chief executive, the board is not discussing Jensen Huang's return, and the shares fell 4.1% on Monday, a day…

Markets

Chip Index Sinks 5.28% With All 30 Stocks Down, Dragging the Nasdaq 2.49% Before Nvidia

The Philadelphia Semiconductor Index fell 5.28% on Monday 16 November with all 30 members down, pulling the Nasdaq 2.49% lower and the Dow down 739 points before Nvidia reports.